Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$97.01

0.46 (0.48%)

08:03
08/07/18
08/07
08:03
08/07/18
08:03

Celltrion applies for trials of AbbVie's Humira biosimilar CT-P17 to MHRA

Celltrion applied for the clinical trials for its adalimumab biosimilar, or CT-P17, as a rheumatoid arthritis therapeutic agent, to the Medicines and Healthcare Products Regulatory Agency, or MHRA, in the UK. Celltrion is set to launch phase 1 clinical trials for the safety and pharmacokinetic assessment of the adalimumab biosimilar in the UK. And Celltrion also conducts global phase 3 clinical trials in about 75 sites in eight nations in European region from August. It aims to complete phase 3 clinical trials by 2020. Abbvie's Humira, the original medicine of CT-P17, is a therapeutic biopharmaceutical for the treatment of rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, ankylosing spondylitis, etc., and it recorded sales of about $18.4B in 2017. Celltrion has developed CT-P17 as a high-concentration formulation and thus differentiated it from the competitive biosimilars which are conducting clinical trials or have already been approved. Meanwhile, after completing clinical trials for CT-P17, Celltrion is set to maximize its market share in TNF-a inhibitor biosimilar markets under the strategy of diversifying its TNF-a inhibitors along with Remsima, already sharing 52%2 of the Europe's original medicine market, and CT-P13 SC which is undergoing clinical trials with the goal of obtaining approvals in 2019.

ABBV AbbVie
$97.01

0.46 (0.48%)

06/15/18
JEFF
06/15/18
NO CHANGE
JEFF
Buy
AbbVie removed from Franchise Pick list at Jefferies
Jefferies analyst Ian Hilliker removed AbbVie from his firm's Franchise Pick list but keeps a Buy rating on the shares with a reduced price target of $125. The stock "continues to have an attractive upside based on its valuation," Hilliker tells investors in a research note.
06/22/18
FBCO
06/22/18
NO CHANGE
Target $89
FBCO
Underperform
AbbVie most exposed to biosimilar risk, says Credit Suisse
Credit Suisse analyst Vamil Divan reiterated an Underperform rating on AbbVie after the FDA further ramped up its focus on biosimilars. In a research note to investors, Divan said he was "intrigued" by the FDA's decision to withdraw its September 2017 Draft Guidance focused on evaluating analytical similarity with biosimilars, and believes the agency will release "more reasonable" guidance in the coming months that will expedite the approval and uptake of biosimilars. AbbVie is most exposed to Biosimilar risk, Divan says, with Humira accounting for about 60% of its total net present value, and is cautious on AbbVie's outlook in front of biosimilar competition in the EU later this year and in the U.S. by 2023.
07/24/18
SBSH
07/24/18
NO CHANGE
SBSH
Buy
Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix
After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences' (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares.
07/27/18
PIPR
07/27/18
NO CHANGE
Target $100
PIPR
Neutral
Worries about AbbVie's Humira keep Piper Jaffray on sidelines
Piper Jaffray analyst Christopher Raymond said he finds "little to quibble with" in AbbVie's Q2 report, but also noted that while its FY18 EPS guidance was raised, its revenue guidance actually came down slightly. Raymond, who continues to worry that consensus does not fully factor in the extent of ex-U.S. Humira pressure or the further pressure from co-pay accumulator programs in the U.S., prefers to stay on the sidelines and keeps a Neutral rating on the shares. He also lowered his price target on AbbVie to $100 from $105.

TODAY'S FREE FLY STORIES

FNMA

Fannie Mae

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Fannie Mae initiated  »

Fannie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMCC

Freddie Mac

$0.00

(0.00%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Freddie Mac initiated  »

Freddie Mac initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Apple initiated  »

Deutsche Bank, fearing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.05

-0.21 (-1.09%)

05:07
06/20/19
06/20
05:07
06/20/19
05:07
Recommendations
JetBlue analyst commentary  »

JetBlue price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

, SNY

Sanofi

$44.11

0.99 (2.30%)

05:05
06/20/19
06/20
05:05
06/20/19
05:05
Recommendations
Voyager Therapeutics, Sanofi, Neurocrine analyst commentary  »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

SNY

Sanofi

$44.11

0.99 (2.30%)

NBIX

Neurocrine

$85.47

-0.28 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

ORCL

Oracle

$52.69

-0.19 (-0.36%)

05:02
06/20/19
06/20
05:02
06/20/19
05:02
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFAM

Bright Horizons

$141.18

1.73 (1.24%)

04:59
06/20/19
06/20
04:59
06/20/19
04:59
Upgrade
Bright Horizons rating change  »

Bright Horizons upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

04:56
06/20/19
06/20
04:56
06/20/19
04:56
Initiation
Enable Midstream initiated  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHDX

Genomic Health

$54.26

-0.04 (-0.07%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Upgrade
Genomic Health rating change  »

Genomic Health upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

SMG

Scotts Miracle-Gro

$98.53

0.4 (0.41%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Scotts Miracle-Gro management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

04:55
06/20/19
06/20
04:55
06/20/19
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 6/15 Jobless…

CVS

CVS Health

$54.89

0.23 (0.42%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
CVS Health participates in a conference call with Morgan Stanley »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CACI

CACI

$206.19

2.03 (0.99%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
CACI to hold a conference call »

Management holds a fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ASB

Associated Banc-Corp

$20.76

-0.1 (-0.48%)

, BFC

Bank First National

$71.11

-2.38 (-3.24%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Sandler O'Neill to hold a field trip »

Wisconsin Community Bank…

ASB

Associated Banc-Corp

$20.76

-0.1 (-0.48%)

BFC

Bank First National

$71.11

-2.38 (-3.24%)

BWB

Bridgewater Bancshares

$11.38

0.19 (1.70%)

CZWI

Citizens Community Bancorp

$10.83

(0.00%)

FBIZ

First Business Financial

$23.41

-0.09 (-0.38%)

ICBK

County Bancorp

$17.19

(0.00%)

NCBS

Nicolet Bankshares

$61.99

0.19 (0.31%)

WSBF

Waterstone Financial

$16.85

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGI

Selective Insurance

$76.39

0.24 (0.32%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Selective Insurance management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

RVNC

Revance

$11.57

0.09 (0.78%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Revance management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 10

    Jul

  • 11

    Jul

AJG

Arthur J. Gallagher

$86.81

0.775 (0.90%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Arthur J. Gallagher management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

BGSF

BG Staffing

$17.46

0.37 (2.17%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
BG Staffing management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

PZZA

Papa John's

$49.15

0.13 (0.27%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Papa John's management to meet with BTIG »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 13

    Nov

SSW

Seaspan

$9.22

0.06 (0.66%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Seaspan management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

NXPI

NXP Semiconductors

$96.25

1.49 (1.57%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
NXP Semiconductors to hold a conference call »

Conference call to review…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 09

    Jul

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
UBS leisure/gaming analyst to hold an analyst/industry conference call. »

Leisure, Gaming &…

TAST

Carrols Restaurant

$8.44

-0.06 (-0.71%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Carrols Restaurant management to meet with Stephens »

Two Days of Meetings to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 13

    Nov

BJRI

BJ's Restaurants

$41.31

-1.29 (-3.03%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
BJ's Restaurants management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

CSL

Carlisle

$138.31

1.67 (1.22%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Carlisle management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.